Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
Identifieur interne : 000979 ( Main/Exploration ); précédent : 000978; suivant : 000980Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
Auteurs : Miguel Angel Martinez [Espagne]Source :
- Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2020.
Abstract
Currently, the expansion of the novel human respiratory coronavirus (known as: SARS-CoV-2, COVID-2019, or 2019-nCoV) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of high-morbidity human coronaviruses, such as the acute respiratory syndrome coronavirus (SARS-CoV) in 2003, and the Middle East respiratory syndrome corona virus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in non-human animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors, lopinavir/ritonavir, and interferon beta (LPV/RTV-INFb) were shown to be effective in patients infected with SARS-CoV. LPV/RTV-INFb also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-INFb against MERS-CoV in a transgenic humanized mice model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, has suggested that pro-inflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aimed to provide a summary of therapeutic compounds that showed potential in fighting SARS-CoV-2 infections.
DOI: 10.1128/AAC.00399-20
PubMed: 32152082
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000686
- to stream PubMed, to step Curation: 000686
- to stream PubMed, to step Checkpoint: 000916
- to stream Ncbi, to step Merge: 000E97
- to stream Ncbi, to step Curation: 000E97
- to stream Ncbi, to step Checkpoint: 000E97
- to stream Main, to step Merge: 000981
- to stream Main, to step Curation: 000979
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Compounds with therapeutic potential against novel respiratory 2019 coronavirus.</title><author><name sortKey="Martinez, Miguel Angel" sort="Martinez, Miguel Angel" uniqKey="Martinez M" first="Miguel Angel" last="Martinez">Miguel Angel Martinez</name><affiliation wicri:level="1"><nlm:affiliation>IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain mmartinez@irsicaixa.es.</nlm:affiliation><country wicri:rule="url">Espagne</country><wicri:regionArea>IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona</wicri:regionArea><wicri:noRegion>Badalona</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32152082</idno><idno type="pmid">32152082</idno><idno type="doi">10.1128/AAC.00399-20</idno><idno type="wicri:Area/PubMed/Corpus">000686</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000686</idno><idno type="wicri:Area/PubMed/Curation">000686</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000686</idno><idno type="wicri:Area/PubMed/Checkpoint">000916</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000916</idno><idno type="wicri:Area/Ncbi/Merge">000E97</idno><idno type="wicri:Area/Ncbi/Curation">000E97</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E97</idno><idno type="wicri:Area/Main/Merge">000981</idno><idno type="wicri:Area/Main/Curation">000979</idno><idno type="wicri:Area/Main/Exploration">000979</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Compounds with therapeutic potential against novel respiratory 2019 coronavirus.</title><author><name sortKey="Martinez, Miguel Angel" sort="Martinez, Miguel Angel" uniqKey="Martinez M" first="Miguel Angel" last="Martinez">Miguel Angel Martinez</name><affiliation wicri:level="1"><nlm:affiliation>IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain mmartinez@irsicaixa.es.</nlm:affiliation><country wicri:rule="url">Espagne</country><wicri:regionArea>IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona</wicri:regionArea><wicri:noRegion>Badalona</wicri:noRegion></affiliation></author></analytic><series><title level="j">Antimicrobial agents and chemotherapy</title><idno type="eISSN">1098-6596</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Currently, the expansion of the novel human respiratory coronavirus (known as: SARS-CoV-2, COVID-2019, or 2019-nCoV) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of high-morbidity human coronaviruses, such as the acute respiratory syndrome coronavirus (SARS-CoV) in 2003, and the Middle East respiratory syndrome corona virus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in non-human animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors, lopinavir/ritonavir, and interferon beta (LPV/RTV-INFb) were shown to be effective in patients infected with SARS-CoV. LPV/RTV-INFb also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-INFb against MERS-CoV in a transgenic humanized mice model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, has suggested that pro-inflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aimed to provide a summary of therapeutic compounds that showed potential in fighting SARS-CoV-2 infections.</div></front></TEI><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Martinez, Miguel Angel" sort="Martinez, Miguel Angel" uniqKey="Martinez M" first="Miguel Angel" last="Martinez">Miguel Angel Martinez</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000979 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000979 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32152082
|texte= Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32152082" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |